Breast imaging is one of the most needed radiology specialties, with one out of eight women affected by breast cancer during her lifetime. Yet breast cancer diagnosis is very challenging, with only 0.5% of mammograms containing cancerous tissue, and 10% of tests yielding false positives.
Paris-based medtech startup Therapixel applies AI to radiology, helping radiologists to better diagnose breast cancer. Founded in 2013, the startup has raised a €5 million Series A round, with Omnes and M Capital Partners joining existing investors Région Sud Investissement, IT-Translation and Credit Agricole.
“Therapixel is entering a new and exciting phase,” said Pierre Fillard, co-founder and CEO of Therapixel. “With this financing round and the strengthening of our governance, I am confident that we will continue to attract the best talents and maintain our leadership.”
Therapixel has demonstrated its ability to develop world’s best AI-based algorithms for breast cancer screening. It won the DREAM Digital Mammography Challenge in 2017, the largest AI competition ever organised, with 1,200 participants and a $1.2 million prize.
“Therapixel has proven to be a leader in the field of AI applied to one of the key challenges in cancer screening,” added Sacha Loiseau, Chairman of Therapixel. “I am delighted to join the company at this key moment and to work hand in hand with Pierre and his team to bring value to our shareholders.”
